首页> 外文期刊>Molecules >Flavonoids from Sideritis Species: Human Monoamine Oxidase (hMAO) Inhibitory Activities, Molecular Docking Studies and Crystal Structure of Xanthomicrol
【24h】

Flavonoids from Sideritis Species: Human Monoamine Oxidase (hMAO) Inhibitory Activities, Molecular Docking Studies and Crystal Structure of Xanthomicrol

机译:铁皮炎物种的类黄酮:人单胺氧化酶(hMAO)抑制活性,分子对接研究和Xanthomicrol的晶体结构。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The inhibitory effects of flavonoids on monoamine oxidases (MAOs) have attracted great interest since alterations in monoaminergic transmission are reported to be related to neurodegenerative diseases such as Parkinson's and Alzheimer's diseases and psychiatric disorders such as depression and anxiety, thus MAOs may be considered as targets for the treatment of these multi-factorial diseases. In the present study, four Sideritis flavonoids, xanthomicrol (1), isoscutellarein 7-O-[6'''-O-acetyl--d-allopyranosyl-(12)]--d-glucopyranoside (2), isoscutellarein 7-O-[6'''-O-acetyl--d-allopyranosyl-(12)]-6''-O-acetyl--d-glucopyranoside (3) and salvigenin (4) were docked computationally into the active site of the human monoamine oxidase isoforms (hMAO-A and hMAO-B) and were also investigated for their hMAO inhibitory potencies using recombinant hMAO isoenzymes. The flavonoids inhibited hMAO-A selectively and reversibly in a competitive mode. Salvigenin (4) was found to be the most potent hMAO-A inhibitor, while xanthomicrol (1) appeared as the most selective hMAO-A inhibitor. The computationally obtained results were in good agreement with the corresponding experimental values. In addition, the x-ray structure of xanthomicrol (1) has been shown. The current work warrants further preclinical studies to assess the potential of xanthomicrol (1) and salvigenin (4) as new selective and reversible hMAO-A inhibitors for the treatment of depression and anxiety.
机译:黄酮类化合物对单胺氧化酶(MAOs)的抑制作用引起了极大的兴趣,因为据报道单胺能传递的改变与帕金森氏病和阿尔茨海默氏病等神经退行性疾病以及抑郁症和焦虑症等精神疾病有关,因此,MAOs可能被认为是靶标用于治疗这些多因素疾病。在本研究中,四种铁皮黄酮类化合物,黄原胶(1),异黄酮7-O- [6'''-O-乙酰基-d-吡喃戊糖基-(12)]-d-吡喃葡萄糖苷(2),异黄酮7- O- [6'''-O-乙酰基-d-吡喃戊糖基-(12)]-6''-O-乙酰基-d-吡喃吡喃糖苷(3)和salvigenin(4)通过计算对接到人单胺氧化酶同工型(hMAO-A和hMAO-B),并使用重组hMAO同工酶研究了它们对hMAO的抑制作用。黄酮类化合物以竞争性方式选择性和可逆地抑制hMAO-A。 Salvigenin(4)被发现是最有效的hMAO-A抑制剂,而xanthomicrol(1)被认为是最具选择性的hMAO-A抑制剂。计算结果与相应的实验值吻合良好。此外,还显示了黄原胶(1)的X射线结构。目前的工作需要进行进一步的临床前研究,以评估黄嘌呤微粉(1)和沙比格列汀(4)作为新的选择性和可逆hMAO-A抑制剂治疗抑郁症和焦虑症的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号